Amphastar Pharmaceuticals Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while ZIM Integrated Shipping Services Ltd trades at $24.65 (market cap $3.04B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 3.5× Amphastar Pharmaceuticals Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ZIM | |
|---|---|---|
Market Cap | $863.95M | $3.04B |
Sector | Health | Industrials |
52-Week High | $30.81 | $29.27 |
52-Week Low | $16.87 | $12.44 |
Enterprise Value | $1.26B | $6.89B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ZIM trades at $26.90, up 1.97% with strong technical momentum (bullish moving averages, RSI at 78.56 suggests overbought conditions). The stock shows mixed fundamentals with a low P/S of 0.48 and P/B of 0.79, but profitability metrics are weak (net margin 1.56%, ROE 2.52%). Recent earnings show one beat and one miss, with Q2 2026 results pending. The company faces merger uncertainty with Hapag-Lloyd amid regulatory challenges.
Outlook remains cautious with analyst consensus neutral (50% hold, 50% sell) and price target of $16.75 well below current levels. Key risks include merger failure, declining cash flow, and geopolitical tensions. The stock trades at a premium to analyst targets despite weak profitability trends, suggesting limited near-term upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →